Literature DB >> 12606078

Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells.

Lizhong Luo1, Yan Li, C Yong Kang.   

Abstract

We have characterized the assembly, budding and extra-cellular release of human immunodeficiency virus (HIV) Gag-Env virus-like particles (VLPs) from human embryonic kidney cells (293 cells expressing the E1a protein of adenovirus) infected with recombinant replication-defective human adenovirus type 5. Recombinant human adenovirus vectors expressing the chimeric Gag-Env protein were constructed by inserting the gag-env fusion gene into the E1a region of the human adenovirus type 5. Biochemical and immunological analyses of VLPs recovered from the culture supernatant revealed that these particles contain the HIV-2 Gag protein and segments of Env protein from the HIV-1 gp120. This chimeric Gag-Env protein interacted with HIV-1 positive patient sera and with HIV-2 Gag monoclonal antibody. Immunoelectron microscopy of the 293 cells infected with the recombinant adenoviruses showed that the HIV Gag-Env antigen is present in the VLPs. Thin-section electron microscopy (EM) revealed that the Gag-Env VLPs bud through the cytoplasmic membrane, as well as through membranes of intracellular vacuoles. The thin-section EM showed that the Gag-Env VLPs have a spherical morphology with an electron-dense ring. The size of VLPs range from 110 to 140 nm in diameter, which is slightly larger than that of the Gag particles without Env protein fusion. Mice immunized with recombinant adenoviruses generated antibodies that specifically reacted with Gag-Env chimeric proteins. Our results support the idea that the replication-defective adenovirus could be used to induce immune responses that might be useful in a vaccine against HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606078     DOI: 10.1016/s0168-1702(02)00316-7

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Authors:  Xuemin Chen; Michael T Rock; Jason Hammonds; James Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie Slike; James E Crowe; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.

Authors:  Antonella Caivano; Nicole A Doria-Rose; Benjamin Buelow; Rossella Sartorius; Maria Trovato; Luciana D'Apice; Gonzalo J Domingo; William F Sutton; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  Virology       Date:  2010-09-20       Impact factor: 3.616

3.  Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles.

Authors:  Lizhong Luo; Yan Li; Soon Duck Ha; C Yong Kang
Journal:  Virus Genes       Date:  2007-05-18       Impact factor: 2.332

4.  Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.

Authors:  Natalia Makarova; Chunxia Zhao; Yuanyuan Zhang; Sushma Bhosle; Suganthi Suppiah; Jeanne M Rhea; Natalia Kozyr; Rebecca S Arnold; Hinh Ly; Ross J Molinaro; Tristram G Parslow; Eric Hunter; Dennis Liotta; John Petros; Jerry L Blackwell
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

5.  Application of the PAMONO-Sensor for Quantification of Microvesicles and Determination of Nano-Particle Size Distribution.

Authors:  Victoria Shpacovitch; Irina Sidorenko; Jan Eric Lenssen; Vladimir Temchura; Frank Weichert; Heinrich Müller; Klaus Überla; Alexander Zybin; Alexander Schramm; Roland Hergenröder
Journal:  Sensors (Basel)       Date:  2017-01-27       Impact factor: 3.576

6.  Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice.

Authors:  Lasse Neukirch; Tea Kirkegaard Nielsen; Henriette Laursen; Joana Daradoumis; Christian Thirion; Peter Johannes Holst
Journal:  Oncotarget       Date:  2019-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.